Abstract
The current study aims to further delineate the associations between the synaptotagmin-like 3 (SYTL3) and solute carrier family 22 member 3 (SLC22A3) single-nucleotide polymorphisms (SNPs) and their haplotypes and gene–gene (G × G)/environment (G × E) interactions on the risk of hyperlipidemia (HLP) in the Maonan and Han ethnic groups. Genotype distribution among the SYTL3–SLC22A3 SNPs in 2,829 individual patients bearing no relationship to each other (Han, 1,436; Maonan, 1,393) was analyzed utilizing next-generation sequencing techniques. The genotype frequencies of the rs6455600, rs2129209, and rs446809 SNPs were varied between the two ethnic groups (P < 0.05–0.001). Various SNPs were correlated with serum levels of triglyceride (TG; rs446809), total cholesterol (TC; rs6455600, rs2129209, and rs539298), and low-density lipoprotein cholesterol (LDL-C; rs446809) among the Han population, whereas various SNPs were also correlated with TC (rs6455600 and rs539298), TG (rs446809), and LDL-C (rs446809) levels in the Maonan ethnic group (P < 0.008–0.001). One part of haplotypes resulted in worsened HLP-related morbidity in the Han (SYTL3 A-C-A-A; SLC22A3 A-A and A-G; and SYTL3–SLC22A3 A-C-A-A-A-A and A-C-A-A-A-G) and Maonan (SYTL3 A-C-A-A; SLC22A3 A-A and A-G; and SYTL3–SLC22A3 A-C-A-A-A-A, G-T-C-A-A-A, and G-T-C-A-C-A) ethnic groups, whereas another part of haplotypes lowered HLP-related health risks in the Han (SLC22A3 C-A and C-G and SYTL3–SLC22A3 A-C-A-A-C-A, A-C-A-A-C-G, and G-T-C-A-C-A) and Maonan (SLC22A3 C-G and SYTL3–SLC22A3 A-C-A-A-C-G) ethnic groups. We discovered that the SYTL3–SLC22A3 SNPs and their haplotypes were associated with serum lipid levels and the risk of HLP in our studied populations.
Highlights
Coronary artery disease (CAD) has become a prominent cause of morbidity, mortality, disability, high healthcare costs, and functional deterioration and accounts for approximately 30% of all deaths worldwide (Yokokawa et al, 2011; Finegold et al, 2013; Houston, 2018)
We noticed that the Maonan population possessed higher levels of lowdensity lipoprotein cholesterol (LDL-C), diastolic blood pressure, apolipoprotein B (ApoB), systolic blood pressure, total cholesterol (TC), TG, weight, alcohol consumption, pulse pressure, and body mass index (BMI) in contrast to the Han group (P < 0.05–0.001)
Systolic blood pressure, TC, waist circumference, ApoB, the proportion of smokers, BMI, alcohol consumption, TG, diastolic blood pressure, pulse pressure, and LDL-C were raised in patients with HLP in contrast to healthy participants in both ethnic groups
Summary
Coronary artery disease (CAD) has become a prominent cause of morbidity, mortality, disability, high healthcare costs, and functional deterioration and accounts for approximately 30% of all deaths worldwide (Yokokawa et al, 2011; Finegold et al, 2013; Houston, 2018). Comprehensive lipidlowering therapy is recommended for patients with CAD by the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the treatment of blood cholesterol to reduce the risk of cardiovascular events (Ray et al, 2014). The guidelines emphasize that lipid-lowering therapy should not focus solely on decreasing low-density lipoprotein cholesterol (LDL-C) levels. Several compelling studies proved that lowering total cholesterol (TC) (Chapman et al, 2011), triglyceride (TG) (Chapman et al, 2011), and LDL-C (Can et al, 2010) levels is more effective in reducing cardiovascular risk than lowering LDL-C levels alone (Ferrieres et al, 2013). HLP appears to be strongly dependent on a person’s genotype, with 40–60% of serum lipid profile variations attributed to hereditary causes (Heller et al, 1993).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
